Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193284 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00193284 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 50 participants.
The verdict
NCT00193284, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
Although gefitinib has been combined successfully with various chemotherapeutic regimens with minimal increase in overall toxicity, experience with concurrent radiation therapy is limited. In this trial, we will evaluate the feasibility, toxicity, and effectiveness a novel combination of chemotherapy, radiation therapy, and gefitinib.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Fluorouracil
- DRUG Gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-10 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193284
The ClinicalTrials.gov registry entry for NCT00193284 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00193284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193284 about?
NCT00193284 is a clinical study titled "Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer". Although gefitinib has been combined successfully with various chemotherapeutic regimens with minimal increase in overall toxicity, experience with concurrent radiation therapy is limited. In this trial, we will evaluate the feasibility, toxicity, and effectiveness a novel combination of chemotherap...
What is the current status of trial NCT00193284?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2003-10. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00193284?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Fluorouracil (DRUG), Gefitinib (DRUG).
Who is sponsoring clinical trial NCT00193284?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.